A Prospective Longitudinal Study of Growth, Development, Fertility and Reproductive Outcomes Among Adolescents and Young Adults With Sickle Cell Anemia With Hydroxyurea
Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY
The SAFE study is a long-term research project that watches people with sickle cell anemia (SCA) over time. The main goal is to see how a medicine called hydroxyurea affects their growth, puberty, and ability to have children. A second goal is to see how hydroxyurea affects pregnancy outcomes, by comparing people who take the medicine to those who don't.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 8
Healthy Volunteers: f
View:
• Patients with documented sickle cell anemia (SCA).
• At least 8 years of age at the time of enrollment.
• Enrolled on the EXTEND or SACRED study.
• Provide informed consent.
• Able to take part in all parts of the study, including treatments, check-ups, and follow-up visits.
Locations
Other Locations
Dominican Republic
Centro de Obstetricia y Ginecologia
RECRUITING
Santo Domingo
Jamaica
Caribbean Institute for Health Research, University of West Indies
RECRUITING
Kingston
United Republic of Tanzania
Buganda Medical Centre
RECRUITING
Mwanza
Contact Information
Primary
Teresa Latham, DrPh
Teresa.Latham@cchmc.org
513-803-7822
Backup
Russell E Ware, MD, PhD
Russell.Ware@cchmc.org
513-803-4597
Time Frame
Start Date: 2023-07-10
Estimated Completion Date: 2035-12-31
Participants
Target number of participants: 250
Treatments
Sickle Cell Anemia
Those with sickle cell anemia (SCA).
Related Therapeutic Areas
Sponsors
Collaborators: Caribbean Institute for Health Research, University of West Indies, Centro de Obstetricia y Ginecologia Recruiting Santo Domingo, Dominican Republic
Leads: Children's Hospital Medical Center, Cincinnati